PhaseBio Pharmaceuticals Inc
PHAS
Get informed when a big investor buys or sells
+ FollowMarket Cap$0
Close$
Share Statistics
| Market cap | $0.00 |
|---|---|
| Enterprise Value | $-1,032,000.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $0 |
| Beta | 2.87 |
| Outstanding Shares | 49,182,813 |
Return
| Return on Equity | -23.71% |
|---|---|
| Return on Assets | 125.58% |
| Return on Invested Capital | -1043.60% |
Valuation & Multiples
| P/E Ratio | -15.72 |
|---|---|
| PEG | 37.9 |
| Price to Sales | - |
| Price to Book Ratio | -0.02 |
| Enterprise Value to Revenue | -1.26 |
| Enterprise Value to EBIT | -0.04 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | -6.56 |
| Debt to Equity | -0.06 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About PhaseBio Pharmaceuticals Inc
CEO: Jonathan Mow